-
Anti-PD-L1: Targeting Tumor Evasion with Immune Checkpoint Blockade(Post)
IntroductionCancer cells have developed sophisticated mechanisms to evade the immune system, particularly through the inhibition of T-cell responses. One such mechanism involves the progr
The Intestinal Barrier: Junctions, Mucus and Permeability(Page) chemokine receptors and ligands(Post)Chemokines are highly conserved cytokines that control the movement of cells around the body. All 45 members of the chemokine family can be divided into 4 subfamilies depending on th
Vibostolimab: Mechanism, Clinical Applications, and Research Potential in Oncology(Post)Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity
Custom Multiplex Assay(Page)Custom Protein & Peptide Service | Assay Genie
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
Unraveling the Mysteries of Platelet-Activating GPCR Signaling(Post)Platelet activation plays a pivotal role in hemostasis, the process that stops bleeding and initiates wound healing. Central to this process is the activation of G protein-coupled receptors (GPCRs
SIRPα Inhibition: Clearing Tumors by Promoting Phagocytosis(Post)Cancer cells are adept at avoiding destruction by the immune system, often exploiting specific pathways to escape detection and elimination. One of these key mechanisms involves the SIRPα
Codrituzumab: Unveiling Its Role in Cancer Research and Treatment(Post)What You Need to Know About CodrituzumabWhat is Codrituzumab?Codrituzumab is an investigational monoclonal antibody targeting CD47, an immune checkpoint that regulates immune responses i
Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
ELISA Troubleshooting: When Standards Read Below the Blank(Post)Quick answer On the GDF-6 (Growth Differentiation Factor 6) ELISA Kit, a researcher saw an elevated blank (OD ≈ 0.41) with the two lowest standards reading at or below it, and no signa
Harnessing CD40 for Potent Anti-Tumor Immune Responses(Post)CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, plays a pivotal role in regulating immune responses, particularly in activating antigen-presenting cells (APCs) an
Diabetic Nephropathy & Diabetic Mellitus(Post)Overview of Diabetes Mellitus Diabetes mellitus (DM) is a major epidemic that affects over 347 million people worldwide (Danaei et al. 2011). The World Hea
Unraveling the Synergy: How Growth Factors Cooperate to Promote Tumorigenesis(Post)In the intricate ballet of cellular communication and regulation, growth factors play pivotal roles in guiding the processes of cell growth, division, and differentiation. These proteins are essen
MAPK Signaling in Inflammatory Cytokines Pathways(Post)Cell Signalling · InflammationMAPK Signalling in Inflammatory Cytokine PathwaysMAPK cascades convert receptor engagement into changes in gene expression, and in inflammation they do it in both directi
Targeting CD200: Unlocking Immune Suppression in Tumors(Post)Immune evasion is one of the hallmarks of cancer, where tumor cells employ various strategies to suppress immune responses and prevent destruction by the body’s defense systems. CD200, a
Cobolimab: Unveiling TIM-3’s Role in Cancer Immunotherapy(Post)Quick Facts About CobolimabWhat is Cobolimab?Cobolimab is a monoclonal antibody that targets TIM-3, a checkpoint protein involved in immune regulation, especially in cancer and autoimmun
Deprotonation: Unveiling the Chemistry Behind It(Post)Chemistry · Acid-BaseDeprotonation: Mechanism, pKa and Choosing the Right BaseDeprotonation is the removal of a proton from a molecule to give its conjugate base. Whether it happens, and how completel
CD4+ T-helper cell differentiation(Page) After Tocilizumab, IL-6 Goes Up. That Is the Drug Working.(Post)Tocilizumab reverses cytokine release syndrome within hours, and it never touches the cell that started it. That sentence contains the whole mechanism. The trigger is a T cell — engaged by a CAR, a b